{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:06:34Z","timestamp":1781939194351,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Uveal effusion syndrome is a rare disease characterized by exudative detachments of the choroid, ciliary body, and retina. Various surgical procedures and nonsurgical strategies have been described to treat uveal effusion syndrome with limited success. The treatment for uveal effusion syndrome remains a serious challenge for clinicians. To the best of our knowledge, no previous report has described a severe uveal effusion syndrome patient with nanophthalmos treated by using an anti-vascular endothelial growth factor agent alone. We report here one such case with unexpected positive results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 30-year-old Chinese male patient presented with painless vision loss in both eyes that had persisted for 2\u00a0months. Examination of the right eye revealed a best corrected visual acuity of 0.03; the best corrected visual acuity of the left eye was finger count\/20\u00a0cm. The intraocular pressure was normal on both eyes. A-scan revealed an right eye axial length of 15.88\u00a0mm and a left eye axial length of 16.21\u00a0mm. In the right eye, half of the peripheral choroid and nearly three-fourths of the retina were detached. The left fundus was not visible because of the total retinal detachment located just behind the lens, which could be clearly observed directly with a slit lamp. Considering all the possibilities and available treatments as well as the patient\u2019s intentions after discussion, we first administered an intravitreal injection of ranibizumab 0.5\u00a0ml into both eyes. The patient\u2019s visual perception improved 3\u00a0days after the injection. One month later, most of the effusion under the choroid and retina was absorbed. Visual acuity improved from finger count to 0.05 in both eyes, and vision quality was remarkably improved. Encouraged by this good result, the patient opted to undergo a second injection 1\u00a0month later. Choroidal and retinal detachment completely vanished 30\u00a0days after the second injection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using an anti-vascular endothelial growth factor agent alone may be a potentially effective and safe method for managing some types of uveal effusion syndrome, such as in nanophthalmos. The injection may be administered before considering more aggressive procedures in some uveal effusion syndrome patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-03101-z","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T23:49:16Z","timestamp":1634600956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rapid resolution of severe exudation in uveal effusion syndrome with anti-vascular endothelial growth factor alone in a case of bilateral nanophthalmos: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Li","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangtian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-7274","authenticated-orcid":false,"given":"Changxian","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"3101_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S0161-6420(82)34685-0","volume":"89","author":"JD Gass","year":"1982","unstructured":"Gass JD, Jallow S. Idiopathic serous detachment of the choroid, ciliary body, and retina (uveal effusion syndrome). Ophthalmology. 1982;89:1018\u201332.","journal-title":"Ophthalmology"},{"key":"3101_CR2","first-page":"1989","volume":"93","author":"RJ Brockhurst","year":"1975","unstructured":"Brockhurst RJ. Nanophthalmos with uveal effusion. A new clinical entity. Arch Ophthalmol. 1975;93:1989\u201399.","journal-title":"Arch Ophthalmol"},{"key":"3101_CR3","first-page":"6578750","volume":"2020","author":"N Yang","year":"2020","unstructured":"Yang N, Jin S, Ma L, Liu J, Shan C, Zhao J. The pathogenesis and treatment of complications in nanophthalmos. J Ophthalmol. 2020;2020:6578750.","journal-title":"J Ophthalmol"},{"key":"3101_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.survophthal.2009.05.003","volume":"55","author":"M Elagouz","year":"2010","unstructured":"Elagouz M, Stanescu-Segall D, Jackson TL. Uveal effusion syndrome. Surv Ophthalmol. 2010;55:134\u201345.","journal-title":"Surv Ophthalmol"},{"key":"3101_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0161-6420(99)00141-4","volume":"107","author":"M Uyama","year":"2000","unstructured":"Uyama M, Takahashi K, Kozaki J, Tagami N, Takada Y, Ohkuma H, et\u00a0al. Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology. Ophthalmology. 2000;107:441\u20139.","journal-title":"Ophthalmology"},{"key":"3101_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/IAE.0b013e318218a95a","volume":"32","author":"TL Jackson","year":"2012","unstructured":"Jackson TL, Hussain A, Salisbury J, Sherwood R, Sullivan PM, Marshall J. Transscleral albumin diffusion and suprachoroidal albumin concentration in uveal effusion syndrome. Retina. 2012;32:177\u201382.","journal-title":"Retina"},{"key":"3101_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00006982-198300330-00003","volume":"3","author":"JD Gass","year":"1983","unstructured":"Gass JD. Uveal effusion syndrome. A new hypothesis concerning pathogenesis and technique of surgical treatment. Retina. 1983;3:159\u201363.","journal-title":"Retina"},{"key":"3101_CR8","first-page":"455","volume":"59","author":"CS Melincovici","year":"2018","unstructured":"Melincovici CS, Bo\u015fca AB, \u015eu\u015fman S, M\u0103rginean M, Mihu C, Istrate M, et\u00a0al. Vascular endothelial growth factor (VEGF)\u2014key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59:455\u201367.","journal-title":"Rom J Morphol Embryol"},{"key":"3101_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1042\/CS20040370","volume":"109","author":"H Takahashi","year":"2005","unstructured":"Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109:227\u201341.","journal-title":"Clin Sci (Lond)"},{"key":"3101_CR10","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s10792-018-0992-1","volume":"39","author":"J Guo","year":"2019","unstructured":"Guo J, Cao X, Li X. Partial thickness sclerectomy and intravitreal anti-VEGF therapy for intractable uveal effusion syndrome. Int Ophthalmol. 2019;39:1885\u201390.","journal-title":"Int Ophthalmol"},{"key":"3101_CR11","first-page":"1862","volume":"103","author":"A Mansour","year":"2019","unstructured":"Mansour A, Stewart MW, Shields CL, Hamam R, Abdul Fattah M, Sheheitli H, et\u00a0al. Extensive circumferential partial-thickness sclerectomy in eyes with extreme nanophthalmos and spontaneous uveal effusion. Br J Ophthalmol. 2019;103:1862\u20137.","journal-title":"Br J Ophthalmol"},{"key":"3101_CR12","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/IAE.0000000000001521","volume":"37","author":"C Ozgonul","year":"2017","unstructured":"Ozgonul C, Dedania VS, Cohen SR, Besirli CG. Scleral surgery for uveal effusion. Retina. 2017;37:1977\u201383.","journal-title":"Retina"},{"key":"3101_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/eye.2014.291","volume":"29","author":"BZ Wang","year":"2015","unstructured":"Wang BZ, Clark B, McKelvie P, Matthews BJ, Buttery RG, Chandra A. Four quadrant sclerotomies for uveal effusion syndrome. Eye (Lond). 2015;29:588\u20139.","journal-title":"Eye (Lond)"},{"key":"3101_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0161-6420(90)32511-3","volume":"97","author":"MW Johnson","year":"1990","unstructured":"Johnson MW, Gass JD. Surgical management of the idiopathic uveal effusion syndrome. Ophthalmology. 1990;97:778\u201385.","journal-title":"Ophthalmology"},{"key":"3101_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.4103\/ijo.IJO_752_17","volume":"65","author":"CL Shields","year":"2017","unstructured":"Shields CL, Roelofs K, Di Nicola M, Sioufi K, Mashayekhi A, Shields JA. Uveal effusion syndrome in 104 eyes: response to corticosteroids\u2014the 2017 Axel C. Hansen lecture. Indian J Ophthalmol. 2017;65:1093\u2013104.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"3101_CR16","doi-asserted-by":"publisher","first-page":"300060519847376","DOI":"10.1177\/0300060519847376","volume":"48","author":"B Tong","year":"2020","unstructured":"Tong B, Wang C, Qi X. Unusual rapid resolution of postsclerectomy exudative retinal detachment with topical NSAIDs therapy in a case of nanophthalmos. J Int Med Res. 2020;48(8):300060519847376.","journal-title":"J Int Med Res"},{"key":"3101_CR17","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.jcjo.2017.04.017","volume":"52","author":"JH Park","year":"2017","unstructured":"Park JH, Lee EK. Medical therapy for bilateral uveal effusion syndrome in nanophthalmos. Can J Ophthalmol. 2017;52:e199\u2013201.","journal-title":"Can J Ophthalmol"},{"key":"3101_CR18","first-page":"319","volume":"99","author":"RN Weinreb","year":"2001","unstructured":"Weinreb RN. Enhancement of scleral macromolecular permeability with prostaglandins. Trans Am Ophthalmol Soc. 2001;99:319\u201343.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"3101_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1001-9294(12)60006-6","volume":"26","author":"W Chan","year":"2011","unstructured":"Chan W, Fang-tian D, Hua Z, You-xin C, Rong-ping D, Ke T. Diagnosis and treatment of uveal effusion syndrome: a case series and literature review. Chin Med Sci J. 2011;26(4):231\u2013620.","journal-title":"Chin Med Sci J"},{"issue":"1","key":"3101_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13816810701651241","volume":"29","author":"OH Sundin","year":"2008","unstructured":"Sundin OH, Dharmaraj S, Bhutto IA, et\u00a0al. Developmental basis of nanophthalmos: MFRPIs required for both prenatal ocular growth and postnatal emmetropization. Ophthalmic Genet. 2008;29(1):1\u20139.","journal-title":"Ophthalmic Genet"},{"issue":"2","key":"3101_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0002-9394(88)90825-2","volume":"106","author":"RC Ward","year":"1988","unstructured":"Ward RC, et\u00a0al. Abnormal scleral findings in uveal effusion syndrome. Am J Ophthalmol. 1988;106(2):139\u201346. https:\/\/doi.org\/10.1016\/0002-9394(88)90825-2.","journal-title":"Am J Ophthalmol"},{"key":"3101_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/ICB.0000000000000357","volume":"11","author":"MM Bausili","year":"2017","unstructured":"Bausili MM, Raja H, Kotowski J, Nadal J, Salomao DR, Keenum D, et\u00a0al. Use of fiberoptic-guided CO2 laser in the treatment of uveal effusion. Retin Cases Brief Rep. 2017;11:191\u20134.","journal-title":"Retin Cases Brief Rep."},{"key":"3101_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00417-008-1020-3","volume":"247","author":"NA Sabrosa","year":"2009","unstructured":"Sabrosa NA, Smith HB, MacLaren RE. Scleral punch method with topical mitomycin C for safe revision of failed deep sclerectomy in nanophthalmic uveal effusion syndrome. Graefes Arch Clin Exp Ophthalmol. 2009;247:999\u20131001.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3101_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3341\/kjo.2013.27.4.294","volume":"27","author":"M Kong","year":"2013","unstructured":"Kong M, Kim JH, Kim SJ, Kang SW. Full-thickness sclerotomy for uveal effusion syndrome. Korean J Ophthalmol. 2013;27:294\u20138.","journal-title":"Korean J Ophthalmol"},{"key":"3101_CR25","first-page":"217","volume":"50","author":"A Kumar","year":"2002","unstructured":"Kumar A, Kedar S, Singh RP. The indocyanine green findings in idiopathic uveal effusion syndrome. Indian J Ophthalmol. 2002;50:217\u20139.","journal-title":"Indian J Ophthalmol"},{"key":"3101_CR26","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/eye.2014.126","volume":"28","author":"BA Derk","year":"2014","unstructured":"Derk BA, Ben\u010di\u0107 G, Corluka V, Geber MZ, Vatavuk Z. Medical therapy for uveal effusion syndrome. Eye (Lond). 2014;28:1028\u201331.","journal-title":"Eye (Lond)"},{"key":"3101_CR27","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1167\/iovs.11-9119","volume":"53","author":"S Nakao","year":"2012","unstructured":"Nakao S, Arima M, Ishikawa K, Kohno R, Kawahara S, Miyazaki M, et\u00a0al. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis. Invest Ophthalmol Vis Sci. 2012;53:4323\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3101_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.exer.2014.06.006","volume":"125","author":"P Mirabelli","year":"2014","unstructured":"Mirabelli P, Peebo BB, Xeroudaki M, Koulikovska M, Lagali N. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. Exp Eye Res. 2014;125:118\u201327.","journal-title":"Exp Eye Res"},{"key":"3101_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/00061198-200212000-00013","volume":"11","author":"C Burgoyne","year":"2002","unstructured":"Burgoyne C, Tello C, Katz LJ. Nanophthalmia and chronic angle-closure glaucoma. J Glaucoma. 2002;11:525\u20138.","journal-title":"J Glaucoma"},{"key":"3101_CR30","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029\u201339.","journal-title":"Am J Pathol"},{"key":"3101_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cxo.12807","volume":"102","author":"MQ Diep","year":"2019","unstructured":"Diep MQ, Madigan MC. Choroidal detachments: what do optometrists need to know? Clin Exp Optom. 2019;102:116\u201325.","journal-title":"Clin Exp Optom"},{"key":"3101_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4103\/2008-322X.170353","volume":"10","author":"S Karimi","year":"2015","unstructured":"Karimi S, Nourinia R, Mashayekhi A. Circumscribed choroidal hemangioma. J Ophthalmic Vis Res. 2015;10:320\u20138.","journal-title":"J Ophthalmic Vis Res"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-03101-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03101-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:18:51Z","timestamp":1634602731000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-03101-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3101"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-03101-z","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We, the Ethics Committee of Da Tong Ophthalmic Hospital, confirm here that this case study involved one middle-aged male patient who suffered from uveal effusion syndrome related to his congenital nanophthalmos on both eyes. This study and medical intervention is in accordance with the Declaration of Helsinki. The doctor in charge of this patient has fully informed the patient of the procedures and the benefits as well as any possible unfavorable outcomes. The patient is willing and accepts this effort.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"515"}}